Literature DB >> 1405773

Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin.

T O'Brien1, J D Silverberg, T T Nguyen.   

Abstract

We report the occurrence of cytopenia and hypothyroxinemia attributed to decreased levels of thyroxine-binding globulin in patients receiving nicotinic acid. We describe two patients in whom hypothyroxinemia developed while they were taking nicotinic acid; these patients also had decreased levels of thyroxine-binding globulin. Results of all thyroid function tests returned to normal when use of the nicotinic acid was discontinued. In one patient, leukopenia and thrombocytopenia developed during nicotinic acid therapy alone. These conditions were reversed after the drug regimen was discontinued. In another patient, leukopenia and thrombocytopenia developed during combination nicotinic acid and lovastatin therapy. When administration of both drugs was discontinued, the hematologic abnormalities, which could have been due to either nicotinic acid or lovastatin, diminished. We suggest that cytopenia may develop in patients receiving nicotinic acid; thus, thyroid function tests should be interpreted in light of a possible decreased level of thyroxine-binding globulin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1405773     DOI: 10.1016/s0025-6196(12)60393-0

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  8 in total

Review 1.  Benefits and harm of niacin and its analog for renal dialysis patients: a systematic review and meta-analysis.

Authors:  Yuan-Mei He; Li Feng; Dong-Mei Huo; Zhen-Hua Yang; Yun-Hua Liao
Journal:  Int Urol Nephrol       Date:  2013-10-11       Impact factor: 2.370

2.  Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis.

Authors:  Radwa El Borolossy; Lamia Mohamed El Wakeel; Ihab El Hakim; Nagwa Sabri
Journal:  Pediatr Nephrol       Date:  2015-09-29       Impact factor: 3.714

3.  A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.

Authors:  Steven C Cheng; Daniel O Young; Yihung Huang; James A Delmez; Daniel W Coyne
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

Review 4.  Niacin and analogs for phosphate control in dialysis--perspective from a developing country.

Authors:  Krishnaswamy Sampathkumar
Journal:  Int Urol Nephrol       Date:  2008-11-27       Impact factor: 2.370

Review 5.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

Review 6.  Nicotinamide and phosphate homeostasis in chronic kidney disease.

Authors:  Charles Ginsberg; Joachim H Ix
Journal:  Curr Opin Nephrol Hypertens       Date:  2016-07       Impact factor: 2.894

Review 7.  N-methyl-2-pyridone-5-carboxamide (2PY)-Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin.

Authors:  Aurélie Lenglet; Sophie Liabeuf; Sandra Bodeau; Loïc Louvet; Aurélien Mary; Agnès Boullier; Anne Sophie Lemaire-Hurtel; Alexia Jonet; Pascal Sonnet; Said Kamel; Ziad A Massy
Journal:  Toxins (Basel)       Date:  2016-11-15       Impact factor: 4.546

Review 8.  Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment.

Authors:  Eun Seong Hwang; Seon Beom Song
Journal:  Biomolecules       Date:  2020-04-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.